Aadi Bioscience signs license agreement for ADC portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2024
0mins
Source: Business Insider
Aadi Bioscience License Agreement: Aadi Bioscience has secured an exclusive license for three preclinical antibody-drug conjugates (ADCs) from WuXi Biologics and Hangzhou DAC, involving upfront payments of $44 million and potential additional milestone payments totaling up to $805 million.
PIPE Financing Support: To facilitate this agreement, Aadi is engaging in a private investment in public equity (PIPE) financing expected to generate approximately $100 million, pending stockholder approval and customary closing conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
